Literature DB >> 2338109

Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects.

A Fujimura1, Y Kumagai, K Sugimoto, H Nakashima, H Kajiyama, A Ebihara, K Ohashi.   

Abstract

Following a cross-over design propranolol 20 mg p.o. was given to 7 healthy subjects at 09.00 h and 21.00 h at an interval of 1 week. Heart rate (HR) during submaximal ergometer exercise was measured at four intervals during 10 h after treatment. Plasma propranolol concentrations were also determined. The suppressive effect (%R) of propranolol on the rise in HR during exercise after the morning dosage was significantly greater at 1.5 h and tended to be greater 3 h after administration than at comparable times in the evening trial. Mean plasma propranolol concentrations during the early phase were higher after the morning than the evening dose. The maximum plasma concentration (Cmax), area under the plasma concentration-time curve from 0 to 10 h (AUC (0-10] and absorption rate constant (ka) were significantly greater after the morning dose. The time to maximum concentration (tmax) and elimination half-life (t 1/2) of the morning and evening dosages did not differ. A significant correlation was observed between plasma propranolol concentration and %R in HR during exercise in the morning (r = 0.74) and evening (r = 0.63) trials, and the regression lines of the morning and evening treatments did not differ.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338109     DOI: 10.1007/bf00265971

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  A theophylline dosage regimen which reduces round-the-clock variations in plasma concentrations resulting from diurnal pharmacokinetic variation.

Authors:  M B Regazzi; R Rondanelli; E Vida; F Farinelli; R A Upton
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Variability of beta-blocker pharmacokinetics in young volunteers.

Authors:  D B Jack; C P Quarterman; R Zaman; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Chronotoxicity of beta-adrenoceptor blocking agent in spontaneously hypertensive rats.

Authors:  A Fujimura; A Ebihara
Journal:  Clin Exp Pharmacol Physiol       Date:  1987-10       Impact factor: 2.557

5.  Circadian variations in the acute toxicity of adrenoceptor blocking agents in spontaneously hypertensive rats.

Authors:  A Fujimura; Y Kumagai; H Kajiyama; A Ebihara
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-11

6.  Time-dependent absorption of theophylline in man.

Authors:  H Watanabe; S Nakano; K Nagai; N Ogawa
Journal:  J Clin Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.126

Review 7.  Circadian changes of drug disposition in man.

Authors:  A Reinberg; M H Smolensky
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

8.  Hydrochlorothiazide diuresis in healthy man: review of the circadian mediation.

Authors:  H W Simpson
Journal:  Nephron       Date:  1979       Impact factor: 2.847

9.  Chronopharmacological study of furosemide in rats: (II). Influence of beta-adrenoceptor blockade.

Authors:  A Fujimura; A Ebihara
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

10.  Timing optimizes sustained-release indomethacin treatment of osteoarthritis.

Authors:  F Levi; C Le Louarn; A Reinberg
Journal:  Clin Pharmacol Ther       Date:  1985-01       Impact factor: 6.875

View more
  6 in total

1.  Cardiac beta 2-adrenoceptors and the inotropic response to exercise in man.

Authors:  C Nyarko-Adomfeh
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

2.  The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects.

Authors:  T Shiga; A Fujimura; T Tateishi; K Ohashi; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  CLOCK-BMAL1 regulates circadian oscillation of ventricular arrhythmias in failing hearts through β1 adrenergic receptor.

Authors:  Zihao Zhou; Jiamin Yuan; Didi Zhu; Yanhong Chen; Zhiyong Qian; Yao Wang; Peibin Ge; Quanpeng Wang; Xiaofeng Hou; Jiangang Zou
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 4.  Challenges and opportunities of pharmaceutical cocrystals: a focused review on non-steroidal anti-inflammatory drugs.

Authors:  Utsav Garg; Yasser Azim
Journal:  RSC Med Chem       Date:  2021-02-09

Review 5.  Therapeutic applications of circadian rhythms for the cardiovascular system.

Authors:  Elena V Tsimakouridze; Faisal J Alibhai; Tami A Martino
Journal:  Front Pharmacol       Date:  2015-04-17       Impact factor: 5.810

6.  Insufficient exercise intensity for clinical benefit? Monitoring and quantification of a community-based Phase III cardiac rehabilitation programme: A United Kingdom perspective.

Authors:  Alaa Khushhal; Simon Nichols; Sean Carroll; Grant Abt; Lee Ingle
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.